These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33952494)

  • 1. Heart Rate Variability as a Non-invasive Objective Parameter for Predicting the Occurrence of Chemotherapy-induced Peripheral Neuropathy in Patients With Gastrointestinal Cancer.
    Jang A; Seol YM
    Anticancer Res; 2021 May; 41(5):2637-2645. PubMed ID: 33952494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study.
    Marstrand SD; Buch-Larsen K; Andersson M; Jensen LT; Schwarz P
    Cancer Treat Res Commun; 2021; 28():100426. PubMed ID: 34186438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate variability and vibration perception threshold to assess chemotherapy-induced neuropathy in women with breast cancer - a systematic review.
    Marstrand SD; Buch-Larsen K; Andersson M; Jensen LT; Schwarz P
    Cancer Treat Res Commun; 2021; 26():100295. PubMed ID: 33387870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials.
    Kishimoto S; Oshima N; Rinker M; Krishna MC; Takebe N
    Eur J Cancer; 2019 Jul; 115():111-119. PubMed ID: 31132741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gabapentin therapy improves heart rate variability in diabetic patients with peripheral neuropathy.
    Ermis N; Gullu H; Caliskan M; Unsal A; Kulaksizoglu M; Muderrisoglu H
    J Diabetes Complications; 2010; 24(4):229-33. PubMed ID: 19195912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy-induced peripheral neuropathy; impact on quality of life].
    Scheel A; Beijers AJ; Mols F; Faber CG; Vreugdenhil G
    Ned Tijdschr Geneeskd; 2014; 158():A7455. PubMed ID: 25315326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.
    Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D
    Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
    Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A
    BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reflexology in the management of chemotherapy induced peripheral neuropathy: A pilot randomized controlled trial.
    Kurt S; Can G
    Eur J Oncol Nurs; 2018 Feb; 32():12-19. PubMed ID: 29353627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
    J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.